Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06342596
Status:
COMPLETED
Last Update Posted:
2024-05-30
First Post:
2024-02-26
Brief Title:
A Study of Carbon-14-Labelled 14C LY3473329 in Healthy Male Participants
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 1 Open-Label Two-Part Study of the Disposition and Absolute Bioavailability of 14C-LY3473329 in Healthy Male Participants
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate how much of the study drug LY3473329 administered as a single dose that has the radioactive substance 14C incorporated into it passes from blood into urine feces and expired air in healthy male participants The study will also measure how much of the study drug gets into the bloodstream when taken orally compared to when injected directly into the vein how its broken down and how long it takes the body to get rid of it The study is conducted in two parts The study will last up to approximately 9 and 7 weeks for part 1 and 2 respectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2O-MC-EKBD | OTHER | Eli Lilly and Company | None |